[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
[^8]
[^9]
[^10]
[^11]
[^12]
[^13]
[^14]
[^15]
[^16]
| Lineage | Neuron > Dysregulated |
| Markers | p-CREB, p-ERK, p-mTOR, p-STAT3, NF-κB |
| Brain Regions | Cerebral Cortex, Hippocampus, Basal Ganglia, Limbic System |
| Disease Relevance | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Autism, Schizophrenia |
[^17]
Dysregulated Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Dysregulated neurons represent a pathological state characterized by abnormal control of intracellular signaling pathways, disrupted homeostasis, and impaired adaptive responses to environmental challenges. Unlike neurons that are simply hyperactive or hypoactive, dysregulated neurons exhibit fundamental errors in their ability to sense, interpret, and respond to cellular signals [1]. This loss of regulatory control manifests at multiple levels: molecular signaling cascades, gene expression programs, metabolic pathways, and network-level computations [2].
The concept of neuronal dysregulation extends beyond simple activity changes. It encompasses the breakdown of intricate feedback mechanisms that normally maintain cellular equilibrium. These mechanisms include homeostatic plasticity, stress response pathways, trophic factor signaling, and circadian regulation [3].
- cAMP/PKA pathway: Abnormal cAMP dynamics disrupt downstream phosphorylation cascades [4]
- MAPK/ERK pathway: Constitutive or impaired ERK activation alters neuronal plasticity [5]
- PI3K/Akt/mTOR pathway: Dysregulated mTOR signaling affects protein synthesis and autophagy [6]
- Calcium signaling: Impaired calcium homeostasis disrupts numerous downstream processes [7]
- CREB dysfunction: Altered CREB-mediated transcription affects survival and plasticity genes [8]
- NF-κB activation: Chronic inflammation drives inappropriate gene expression [9]
- FOXO mislocalization: Impaired stress response gene regulation [10]
- Epigenetic alterations: Histone modifications and DNA methylation changes [11]
- Glucose metabolism: Altered glycolysis and oxidative phosphorylation [12]
- Lipid metabolism: Disrupted membrane composition and lipid signaling [13]
- Amino acid metabolism: Impaired neurotransmitter synthesis [14]
- Energy homeostasis: ATP/AMP ratio disruptions affect all cellular processes [15]
- Abnormal spine morphology: Irregular spine shapes indicate synaptic instability [16]
- Impaired vesicle cycling: Altered release probability and replenishment [17]
- Receptor trafficking errors: Mislocalized ionotropic and metabotropic receptors [18]
- Synaptic protein aggregates: Misfolded proteins at presynaptic terminals [19]
- Microtubule instability: Tau pathology disrupts axonal transport [20]
- Actin dynamics alterations: Impaired spine plasticity and motility [21]
- Intermediate filament disorders: Neurofilament abnormalities affect axonal integrity [22]
- Axonal transport deficits: Kinesin/dynein dysfunction [23]
- Mitochondrial fragmentation: Impaired fusion/fission balance [24]
- ER stress: Unfolded protein response activation [25]
- Lysosomal impairment: Autophagy-lysosome pathway deficits [26]
- Golgi apparatus fragmentation: Disrupted protein processing [27]
- APP processing dysregulation: Abnormal amyloid precursor protein cleavage [28]
- Aβ oligomer toxicity: Synaptic dysregulation through multiple mechanisms [29]
- BACE1 hyperactivity: Enhanced amyloidogenic processing [30]
- Hyperphosphorylation: Dissociation of tau from microtubules [31]
- Oligomer formation: Toxic tau species spread between neurons [32]
- Axonal transport disruption: Tau-mediated transport deficits [33]
- NMDA receptor overactivation: Excitotoxic calcium influx [34]
- ER calcium depletion: Store-operated calcium entry abnormalities [35]
- Mitochondrial calcium overload: Permeability transition pore opening [36]
- Oligomer formation: Toxic alpha-synuclein species [37]
- Lewy body formation: Intraneuronal inclusions disrupt function [38]
- Synaptic vesicle binding: Impairs neurotransmitter release [39]
- Tyrosine hydroxylase dysfunction: Impaired dopamine synthesis [40]
- Vesicular monoamine transporter: Altered dopamine packaging [41]
- Dopamine receptor signaling: Downstream pathway dysregulation [42]
- Complex I deficiency: Reduced ATP production [43]
- ROS overproduction: Oxidative stress accumulation [44]
- Mitophagy impairment: Accumulation of dysfunctional mitochondria [45]
- Neurexin/neuroligin dysfunction: Impaired synapse formation [46]
- SHANK protein deficits: Postsynaptic density abnormalities [47]
- mTOR hyperactivation: Enhanced protein synthesis [48]
- Excitation-inhibition imbalance: Altered E/I ratio [49]
- Cortical connectivity changes: Modified network properties [50]
- Sensory processing abnormalities: Enhanced sensory responses [51]
- D1 hypofunction: Prefrontal cortex working memory deficits [52]
- D2 hyperfunction: Striatal signaling abnormalities [53]
- Presynaptic dopamine dysfunction: Altered synthesis and release [54]
- NMDA receptor hypofunction: Synaptic plasticity deficits [55]
- AMPA receptor trafficking: Altered receptor composition [56]
- Metabotropic glutamate signaling: Group I mGluR dysfunction [57]
- Phosphodiesterase inhibitors: Enhance cAMP signaling [58]
- MAPK pathway modulators: Normalize ERK activity [59]
- mTOR inhibitors: Reduce hyperactivation in autism [60]
- Ketogenic diet: Alternative energy metabolism [61]
- Pyruvate supplementation: Enhanced metabolic support [62]
- Antioxidants: Reduce oxidative stress [63]
- Viral vector delivery: Target specific dysregulated pathways [64]
- CRISPR-based approaches: Correct genetic causes [65]
- RNA therapeutics: Modulate expression of dysregulated genes [66]
- Patient-derived iPSCs: Model disease-specific dysregulation [67]
- Primary neuron cultures: Manipulate signaling pathways [68]
- Organoid systems: Complex network dysregulation [69]
- Transgenic models: Disease-causing mutations [70]
- Knockout models: Specific pathway disruption [71]
- [Optogenetic manipulation: Precise temporal control of signaling [72]